Presidential Cancer Panel Demands More Children Receive HPV Vaccine
The President’s Cancer Panel (PCP) is demanding that federal and state authorities spend more resources into ensuring that children are inoculated with the human papillomavirus virus vaccine to prevent reproductive cancer development.
HPV vaccine manufacturers GlaxoSmithKline Merck are expecting profit surges because of their products: Cervix and Gardasil.
Currently, estimates assume that a 3rd of teenage girls have been exposed to the HPV vaccines available, while only 7% of boys have received the inoculation.
Barbara Rimer, chair of the PCP said : “We are confident that if HPV vaccination for girls and boys is made a public health priority, hundreds of thousands will be protected from these HPV-associated diseases and cancers over their lifetimes.”
Young men are being targeted for HPV as the Centers for Disease Control and Prevention (CDC) says is correlated with the development of genital warts; as well as cancer of the throat, tonsils, base of the tongue, anus and penis.
Gardasil, the vaccination being given to both young men and women to prevent HPV, is manufactured by Merck Pharmaceuticals.
Information in the insert for Gardasil states that the vaccine has not been tested for carcinogenicity. In this instance, there is no evidentiary reason for Gardasil to be used to combat HPV or as a preventative for reproductive cancers.
According to Dr. Charlotte Haug on the validity of Gardasil: “There is another serious question that may be answered sooner: what effect will the vaccine have on the other cancer-causing strains of HPV? Nature never leaves a void, so if HPV-16 and HPV-18 are suppressed by an effective vaccine, other strains of the virus will take their place. The question is, will these strains cause cervical cancer?”
Haug continues: “Results from clinical trials are not encouraging. Vaccinated women show an increased number of precancerous lesions caused by strains of HPV other than HPV-16 and HPV-18. The results are not statistically significant, but if the trend is real – and further clinical trials should tell us in a few years – there is reason for serious concern.”
The Food and Drug Administration (FDA) agreed to approve Gardasil in the US under the condition that all-inclusive research were conducted before it would be placed on a children’s scheduled vaccination program.
The contract between the FDA and Merck states: “You have committed to conduct a study in collaboration with the Norwegian Government, if GARDASIL is approved in the European Union and the Government of Norway incorporates HPV vaccination into its national guidelines, to assess the impact of HPV vaccination on the following in Norway … to assess whether administration of GARDASIL will result in replacement of these diseases due to vaccine HPV types with diseases due to non-vaccine HPV types.”
In studies there has been a palatiable increase in those who are exposed to HPV who have also received the Gardasil vaccine to develop cancer.
It was found that in “peer-reviewed analysis and studies many of them on the FDA, NCI and CDC web sites point out the dangers of many of the vaccine ingredients including the potential for the HPV vaccines to increase the risk for pre-cancerous lesions if adolescents have been previously exposed to the human papillomavirus and then get vaccinated: 44.6% increase post Gardasil.”
Most shocking is that in a test taken from 13 samples of Gardasil, it was discovered that “all the samples contained recombinant (genetically modified) HPV DNA which was firmly attached to the aluminum adjuvant.”
This recombinant HPV DNA is considered bio-hazardous with effects unknown to the medical community.
It was stated : “Based on medical literature and some of the FDA/Merck’s own publications, adventitious (coming from an outside source) DNA in an injectable protein-based vaccine may increase the risk of autoimmune disorders and gene mutation which may lead to malignancies.”